ENA Respiratory, an Australian clinical stage drug researcher, has collaborated with the COPD Foundation, a nonprofit with a mission to improve the lives of those affected by COPD and other lung conditions, to develop its first-in-class, broad-spectrum antiviral nasal spray — known as INNA-051 — for populations at risk of developing complications from respiratory viral infections, including COVID-19. INNA-051 is a potent activator of the innate immune system, which is delivered as a spray to the nasal cavity, and that the antiviral therapy can be given before or after an infection sets in. ENA also plans to conduct a phase 2 trial to confirm the antiviral potential of INNA-051 in up to 423 adults who had household contact with an individual with a confirmed SARS-CoV-2 infection.